A sustainable business model based on innovation and ... - Roche

More documents

Recommendations

Info

Q1 2009: High single-digit growth for both divisions Well above world market CHF bn % change in Q1’08 Q1’09 CHF local Pharmaceuticals 8.6 9.2 8 8 Diagnostics 2.3 2.4 3 8 Roche Group 10.9 11.6 7 8 4
Performance up-date Our Strategy and the changing environment Main trends influencing long term value propositions Summary 5
Page 1 and 2: Roche A sustainable</strong
Page 3: Performance up-date Strategy Main t
Page 7 and 8: Focus on our core business<
Page 9 and 10: Not to invest in the future means b
Page 11 and 12: Responsible management of R&D spend
Page 13 and 14: Main trends influencing the long-te
Page 15 and 16: Scenarios for PHC Added Value Distr
Page 17 and 18: Key drivers for long term developme
Page 19 and 20: Major growth opportunities outside
Page 21 and 22: First in class mechanisms establish
Page 23 and 24: Avastin: significant potential for
Page 25 and 26: ASCO 2009 Highlights Avastin NSABP
Page 27 and 28: Rheumatoid Arthritis: Not all patie
Page 29 and 30: Performance up-date Strategy Main t
Page 31 and 32: Profitability measures Operating ca
Page 33 and 34: Patent expiry 2008-2012 Roche short
Page 35 and 36: We Innovate Healthcare 35
Page 37: Top 10 Oncology Products Sales and

A sustainable business model based on innovation and ... - Roche

Create successful ePaper yourself

Delete template?

Save as template?